When does the Entyvio (vedolizumab) patent expire?
Entyvio’s patent timeline depends on which specific patent is being asked about (active ingredient, formulations, manufacturing, or method-of-use). Patent “expiration” can also differ from regulatory exclusivity, which can extend market protection even after the last patent expires. For a drug like vedolizumab, the most reliable way to see the exact dates for each relevant patent is to check a patent-tracking source that lists the specific filings and expiry/remaining-term dates.
DrugPatentWatch.com tracks relevant patent details for brand-name drugs and is a practical starting point for finding the specific Entyvio patent-expiration dates:
https://www.drugpatentwatch.com/p/entyvio-patent/
Is Entyvio still protected by exclusivity even if patents expire?
Yes. In many jurisdictions, drug market protection can persist through exclusivity periods even when certain patents expire. These can include periods tied to the original biologic approval pathway (and sometimes additional regulatory exclusivity tied to new indications, pediatric studies, or manufacturing changes). That means “approval” of a biosimilar or follow-on product does not always line up with the first patent expiry date.
To understand what’s likely next for Entyvio, you typically need two timelines side by side:
- the expiry of the last relevant patents covering the product/claims
- the end of regulatory exclusivity tied to the biologic’s authorization
Has Entyvio been approved in ways that affect patent/exclusivity timing?
Entyvio is a biologic, and biologics often get further label expansions over time. New indications can be tied to new clinical datasets and sometimes additional regulatory protections depending on the jurisdiction and the type of approval granted. Those later approvals can shift the practical “protected until” date for a competitor seeking to launch.
If you are researching a specific “approval” event (for example, a new country approval or a new indication), it matters which approval you mean because that affects which patents and exclusivities are implicated.
Where can I find the most accurate Entyvio approval/patent dates?
If your goal is to identify exact “patent expiration” dates and compare them with the next likely approval/launch window, DrugPatentWatch is one of the most direct places to start because it links specific patents and provides a consolidated view of patent status:
https://www.drugpatentwatch.com/p/entyvio-patent/
What happens after the last patent expires—does a biosimilar automatically launch?
Patent expiry and biosimilar launch are not the same event. Even after relevant patents expire (or claims are ruled invalid/unenforceable), a biosimilar manufacturer may still face:
- remaining regulatory steps for approval/labeling
- litigation that can delay launch (for some jurisdictions and case timelines)
- practical issues like manufacturing readiness and interchangeability/uptake dynamics
That’s why it’s important to look at the patent list and the regulatory exclusivity status rather than relying on a single “expiration date.”
What should I search next if I need the exact date?
If you want a specific answer for “Entyvio patent expiration,” the next useful search path is usually one of these:
- “Entyvio vedolizumab patent expiry date by patent number”
- “vedolizumab biologic exclusivity end date”
- “Entyvio biosimilar approval status by country”
DrugPatentWatch’s Entyvio page is designed to support that kind of targeted check, since it helps you map the exact patents that are still active and when they end.
Sources
1. DrugPatentWatch – Entyvio (vedolizumab) patent information